Plan B sNDA
This article was originally published in The Tan Sheet
Executive Summary
PDUFA decision date for Plan B OTC supplemental NDA is Jan. 20, Barr says at Banc of America Securities conference in San Francisco, Sept. 23. The Woodcliff Lake, N.J.-based generics firm submitted "information supporting the marketing of Plan B as a prescription-only product for women 15 years of age and younger and a nonprescription product for women 16 years of age and older," Barr said in July (1"The Tan Sheet" July 26, 2004, p. 5)...
You may also be interested in...
Barr Submits Plan B Response To FDA, Starts 180-Day Review Clock
An FDA decision on OTC availability of Barr Labs' Plan B emergency contraceptive is expected by the end of January
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.